ThinPrep Pricing Level Improvement Drives Cytyc Q1 Revenues To $72.6 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Cytyc anticipates a second quarter launch for the ThinPrep automated imaging and review system, which is used with the company's cervical cancer screening test
You may also be interested in...
Digene Infrastructure Scale-Up For DNA Pap Could Follow Failed Cytyc Merger
Digene may decide to expand its sales infrastructure for marketing the HPV DNA Pap test as a primary screen for cervical cancer if its pending merger with Cytyc does not occur
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.